Management of HCTZ in Patients with Acute Illness or Unknown Baseline Labs
Clinical Context for Holding HCTZ
- The American Journal of Kidney Diseases recommends that thiazide diuretics, including HCTZ, should be temporarily stopped during acute illness with volume depletion, with 90% expert agreement 1, 2
- HCTZ should be held if the patient has signs/symptoms of vomiting, diarrhea, fever, reduced oral intake, or orthostatic symptoms, as recommended by the American Journal of Kidney Diseases 1
- The duration of holding HCTZ is up to 3 days initially, and it should be continued until signs and symptoms have resolved, as per the American Journal of Kidney Diseases 1, 2
Evidence for Electrolyte Monitoring
- Impaired renal function increases plasma concentrations and elimination half-life of HCTZ, according to the British Journal of Pharmacology 4
- Long-term therapy with HCTZ for ≥5 years is associated with a higher risk of hypokalaemia, as reported by Praxis Medical Insights 3
Timing of Lab Monitoring
- The British Journal of Pharmacology recommends monitoring renal function within 1-2 weeks after starting HCTZ therapy, with more frequent monitoring for patients with chronic kidney disease or baseline electrolyte abnormalities 4
- Praxis Medical Insights suggests monitoring electrolytes and renal function within 4 weeks of initiation or dose escalation of HCTZ 3